Therapeutics and Clinical Risk Management, 2019 Chiara Lupi,1 Simona Guerzoni,2 Andrea Negro,3 Silvia Benemei1 1Headache Centre, Careggi University Hospital, Department of Health Sciences, University of Florence, Florence, Italy; 2Medical Toxicology Unit, Headache and Drug Abuse Centre, Department of
Lupi C, Guerzoni S, Negro A, Benemei S
doaj
Efficacy of Rimegepant Plus Calcitonin Gene-Related Peptide Monoclonal Antibody for Migraine [PDF]
, 2021 Migraine is a paroxysmal pain disorder managed with abortive therapy during a pain attack, prophylactic therapy to prevent attacks, and often a combination of both. Calcitonin gene-related peptide (CGRP) and its receptor have a role in the provocation of
Leggio, Carina
core +1 more source
Are we closer to achieving precision medicine for migraine treatment? A narrative review [PDF]
Migraine; Prediction; TreatmentMigraña; Predicción; TratamientoMigranya; Predicció; TractamentBackground The term ‘precision medicine’ encompasses strategies to optimize diagnosis and outcome prediction and to tailor treatment for individual patients ...
Casillo, Francesco +6 more
core +2 more sources
Galcanezumab-induced fixed drug eruption [PDF]
JAAD Case Reports, 2021 Skylar Klager, SM +3 more
openaire +3 more sources
Switching anti-CGRP monoclonal antibodies in chronic migraine:real-world observations of erenumab, fremanezumab and galcanezumab [PDF]
Objectives: The anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP-mAb) are effective in migraine; however, few studies have examined the benefit of switching from one anti-CGRP-mAb to another.
Crossingham, Ginette +5 more
core +1 more source
Monoclonal antibodies for migraine: an update [PDF]
, 2018 Castle, Daniel, Robertson, Neil P.
core +2 more sources
Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies [PDF]
Antibodies; Gepant; Migraine disordersAnticuerpos; Gepant; Trastornos de migrañaAnticossos; Gepant; Trastorns de migranyaBackground To evaluate the benefit-risk assessment of atogepant and calcitonin gene–related peptide (CGRP) monoclonal antibodies ...
Ailani, Jessica +6 more
core +1 more source
Pain and TherapyIntroduction The efficacy of galcanezumab has been demonstrated in randomized controlled trials, but evidence about its use under clinical practice conditions is still limited. This study aimed to describe the characteristics of the patients treated with
Samuel Díaz Insa +9 more
doaj +1 more source
Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review [PDF]
Background: Migraine is the second most common prevalent disorder worldwide and is a top cause of disability with a substantial economic burden. Many preventive migraine medications have notable side effects that affect different body organs.
Aksentyte, Aiva +7 more
core
Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine:A systematic review and potential clinical implications [PDF]
Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or the CGRP-receptor have revolutionized the prevention of migraine. Despite their effectiveness, worries have surfaced regarding potential unwanted cardiovascular effects
Olsen, Michael H. +5 more
core +3 more sources